Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Company Overview - Perspective Therapeutics, Inc. is a radiopharmaceutical development company focused on advanced treatment applications for cancers throughout the body [2] - The company utilizes proprietary technology with the alpha-emitting isotope Pb to deliver targeted radiation specifically to cancer cells [2] - Perspective is also developing complementary imaging diagnostics that enhance treatment personalization and optimize patient outcomes through a "theranostic" approach [2] Current Developments - The company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs are currently in Phase 1/2a imaging and therapy trials in the U.S. [3] - Perspective is expanding its regional network of drug product finishing facilities, supported by its proprietary Pb generator, to provide patient-ready products for clinical trials and commercial operations [3] Upcoming Events - The company will report its full year 2024 financial results and provide a business update on March 26, 2025, after market close [1]